Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection (original) (raw)

• Plotkin, S.A., Orenstein, W.A. & Offit, P.A. Vaccines: Expert Consult (Saunders, 2008).
• Fiore, A.E. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep. 59, 1–62 (2010).
  PubMed Google Scholar
• Doherty, P.C., Turner, S.J., Webby, R.G. & Thomas, P.G. Influenza and the challenge for immunology. Nat. Immunol. 7, 449–455 (2006).
  Article CAS Google Scholar
• Salomon, R. & Webster, R.G. The influenza virus enigma. Cell 136, 402–410 (2009).
  Article CAS Google Scholar
• Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A. & Martin, M.A. Fields Virology (Lippincott Williams & Wilkins, 2006).
• Tong, S. et al. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. USA 109, 4269–4274 (2012).
  Article CAS Google Scholar
• de Jong, J.C., Beyer, W.E., Palache, A.M., Rimmelzwaan, G.F. & Osterhaus, A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 61, 94–99 (2000).
  Article CAS Google Scholar
• Ulmer, J.B., Valley, U. & Rappuoli, R. Vaccine manufacturing: challenges and solutions. Nat. Biotechnol. 24, 1377–1383 (2006).
  Article CAS Google Scholar
• Lambert, L.C. & Fauci, A.S. Influenza vaccines for the future. N. Engl. J. Med. 363, 2036–2044 (2010).
  Article CAS Google Scholar
• Nabel, G.J. & Fauci, A.S. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16, 1389–1391 (2010).
  Article CAS Google Scholar
• Forde, G.M. Rapid-response vaccines—does DNA offer a solution? Nat. Biotechnol. 23, 1059–1062 (2005).
  Article CAS Google Scholar
• Liu, M.A. Immunologic basis of vaccine vectors. Immunity 33, 504–515 (2010).
  Article CAS Google Scholar
• Thalhamer, J., Weiss, R. & Scheiblhofer, S. Gene Vaccines (Springer, Wien and New York; 2011).
• Hoerr, I., Obst, R., Rammensee, H.G. & Jung, G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30, 1–7 (2000).
  Article CAS Google Scholar
• Fotin-Mleczek, M. et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34, 1–15 (2011).
  Article CAS Google Scholar
• Sebastian, M. et al. Messenger RNA vaccination in NSCLC: findings from a phase I/IIa clinical trial. J. Clin. Oncol. 29 (suppl; abstr 2584) (2011).
  Article Google Scholar
• Kübler, H. et al. Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. J. Clin. Oncol. 29 (suppl; abstr 4535) (2011).
  Article Google Scholar
• Potter, C.W. & Oxford, J.S. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35, 69–75 (1979).
  Article CAS Google Scholar
• Plotkin, S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401–409 (2008).
  Article Google Scholar
• Brown, D.M., Dilzer, A.M., Meents, D.L. & Swain, S.L. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177, 2888–2898 (2006).
  Article CAS Google Scholar
• Galli, G. et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 106, 3877–3882 (2009).
  Article CAS Google Scholar
• Hamada, H. et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 182, 3469–3481 (2009).
  Article CAS Google Scholar
• Wilkinson, T.M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274–280 (2012).
  Article CAS Google Scholar
• Deng, Y., Yewdell, J.W., Eisenlohr, L.C. & Bennink, J.R. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158, 1507–1515 (1997).
  CAS PubMed Google Scholar
• Boon, A.C.M. et al. Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. J. Virol. 84, 7662–7667 (2010).
  Article CAS Google Scholar
• McMichael, A.J., Gotch, F.M., Noble, G.R. & Beare, P.A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309, 13–17 (1983).
  Article CAS Google Scholar
• Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745–1749 (1993).
  Article CAS Google Scholar
• Rimmelzwaan, G.F., Fouchier, R.A.M. & Osterhaus, A.D.M.E. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18, 529–536 (2007).
  Article CAS Google Scholar
• Kistner, O. et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS ONE 5, e9349 (2010).
  Article Google Scholar
• Chaloupka, I., Schuler, A., Marschall, M. & Meier-Ewert, H. Comparative analysis of six European influenza vaccines. Eur. J. Clin. Microbiol. Infect. Dis. 15, 121–127 (1996).
  Article CAS Google Scholar
• Belshe, R.B. Translational research on vaccines: influenza as an example. Clin. Pharmacol. Ther. 82, 745–749 (2007).
  Article CAS Google Scholar
• van der Laan, J.W. et al. Animal models in influenza vaccine testing. Expert Rev. Vaccines 7, 783–793 (2008).
  Article CAS Google Scholar
• Van Reeth, K., Labarque, G., De Clercq, S. & Pensaert, M. Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection. Vaccine 19, 4479–4486 (2001).
  Article CAS Google Scholar
• Pyo, H.-M. et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine 30, 1297–1304 (2012).
  Article CAS Google Scholar
• Lefevre, E.A. et al. Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes. PLoS ONE 7, e32400 (2012).
  Article CAS Google Scholar
• Laurent, P.E. et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25, 8833–8842 (2007).
  Article CAS Google Scholar
• Dormitzer, P.R., Ulmer, J.B. & Rappuoli, R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26, 659–667 (2008).
  Article CAS Google Scholar
• Johansson, D.X., Ljungberg, K., Kakoulidou, M. & Liljeström, P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE 7, e29732 (2012).
  Article CAS Google Scholar
• Fotin-Mleczek, M. et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene Med. 14, 428–439 (2012).
  Article CAS Google Scholar
• Schlake, T. et al. Developing mRNA-vaccine technologies. RNA Biol. (in the press) (2012).
  Article CAS Google Scholar
• Pascolo, S. Vaccination with messenger RNA. Methods Mol. Med. 127, 23–40 (2006).
  CAS PubMed Google Scholar
• Pascolo, S. Vaccination with messenger RNA (mRNA). Handb. Exp. Pharmacol. 221–235 (2008) doi:10.1007/978-3-540-72167-3_11.
  Chapter Google Scholar
• Reed, L.J. & Muench, H. A simple method of estimation of fifty percent end points. Am. J. Hyg. 27, 493–497 (1938).
  Google Scholar
• Hai, R. et al. PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J. Virol. 84, 4442–4450 (2010).
  Article CAS Google Scholar
• Cobbold, S.P., Jayasuriya, A., Nash, A., Prospero, T.D. & Waldmann, H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312, 548–551 (1984).
  Article CAS Google Scholar
• Lange, E. et al. Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs. J. Gen. Virol. 90, 2119–2123 (2009).
  Article CAS Google Scholar
• Hoffmann, B. et al. New real-time reverse transcriptase polymerase chain reactions facilitate detection and differentiation of novel A/H1N1 influenza virus in porcine and human samples. Berl. Munch. Tierarztl. Wochenschr. 123, 286–292 (2010).
  CAS PubMed Google Scholar